Naltrexone-Bupropion (Contrave): A Clinical Guide

Written by Empire Medical Training Editorial Team

Medically reviewed by Betsy Greenleaf, DO Board-Certified OB/GYN & Urogynecologist; Empire Director of Anti-Aging

Updated June 2026 ·12 min read

Naltrexone-bupropion is an FDA-approved oral medication for chronic weight management, marketed as Contrave. What makes it distinctive is that neither of its ingredients was originally a weight-loss drug. Bupropion is an antidepressant and smoking-cessation agent; naltrexone is an opioid antagonist from addiction medicine. Combined, they act on two different parts of the brain at once — the appetite-control circuitry of the hypothalamus and the reward pathway that drives craving — and that dual action is exactly why the combination matters clinically.

This guide situates Contrave within the broader field of medical weight loss and is written for clinicians who want an accurate, practical overview. It is clinical education, not medical advice, and nothing here should be read as a treatment recommendation, protocol, or substitute for current FDA labeling.

What is naltrexone-bupropion?

Naltrexone-bupropion is a fixed-dose combination of two long-established drugs, each well known on its own. Bupropion — commonly recognized as Wellbutrin — is FDA-approved for depression and smoking cessation, and weight loss is an off-label property of the molecule that has been observed for years. Naltrexone is an opioid antagonist used primarily in substance-use treatment. Neither, given alone, is the FDA-approved answer to obesity. Put together as Contrave, however, they form a single product with an FDA approval for chronic weight management.

The combination is deliberate, not incidental. As Empire faculty teach it, the two agents “work synergistically” — each addresses a different aspect of weight regulation, and the value of the product is in how those mechanisms complement one another. Understanding that synergy is the key to understanding which patients it suits.

How Contrave works

Bupropion is a weak reuptake inhibitor of dopamine and norepinephrine, and that neurotransmitter activity is part of how it reduces appetite and modestly raises energy expenditure. The more important mechanism for weight loss, though, runs through a specific population of cells in the brain.

Bupropion and the POMC neurons

Bupropion stimulates pro-opiomelanocortin (POMC) neurons in the hypothalamus, the region of the brain that governs appetite. When these neurons fire, they suppress hunger and increase energy expenditure — exactly the direction a weight-loss agent wants to push. On its own, however, this effect tends to be self-limiting. POMC neurons release beta-endorphin as part of their activity, and that endorphin loops back and binds the neurons' own opioid receptors, telling them to quiet down. In other words, the appetite-suppressing system has a built-in autoinhibitory feedback loop that throttles itself.

Naltrexone releases the brake

This is where naltrexone earns its place in the formulation. As an opioid antagonist, naltrexone blocks that autoinhibitory feedback — it sits on the opioid receptors so the endorphin signal can no longer switch the POMC neurons off. The result is that bupropion's appetite-suppressing effect keeps working instead of being damped down. The two drugs are not redundant; naltrexone is, in effect, removing the brake that limits what bupropion can do.

The reward pathway and craving

Naltrexone contributes a second, independent mechanism. By acting on the brain's mesolimbic reward pathway, it can blunt the reward and pleasure response associated with food. Faculty describe naltrexone as “particularly effective for individuals struggling with reward-based or emotional eating behaviors” — patients whose eating is driven less by physiological hunger than by the gratification food provides. Where bupropion turns down the appetite signal, naltrexone turns down the craving and the reward, which is why the combination addresses a kind of eating that portion control alone rarely fixes.

FDA status

Naltrexone-bupropion is FDA-approved for chronic weight management as Contrave, used together with a reduced-calorie diet and increased physical activity in eligible patients. This is an important honesty point for patients: while bupropion's individual weight effect is off-label and naltrexone alone is not a weight-loss drug, the combination product carries a genuine FDA approval for this indication. Providers should always work from current approved labeling for eligibility, titration, and contraindications rather than improvising with the two component drugs separately.

Efficacy and evidence

The weight loss seen with naltrexone-bupropion is meaningful but moderate, and it is realistic to frame it that way for patients. Studies of the combination show roughly a five to eleven-and-a-half percent reduction in body weight, with results at the higher end of that range tied to patients who pair the medication with intensive diet and lifestyle change — in some cases reaching ten to fifteen percent. The bupropion component alone has demonstrated weight loss superior to placebo, with one regimen showing about five percent over placebo at eight weeks and nearly thirteen percent at twelve weeks.

The central caveat is the one Empire faculty emphasize across every weight-loss agent: the medication is not a standalone solution. Diet and lifestyle modification are essential for significant and sustainable results, and the drug works best as a lever applied on top of behavioral change rather than as a substitute for it. Setting that expectation early is part of using the medication well.

Side effects

Naltrexone-bupropion is generally well tolerated, but it has a characteristic side-effect profile that providers should counsel patients on in advance. Nausea is the most common side effect by a wide margin. Beyond that, patients may experience constipation, headache, insomnia, dizziness, and vomiting, and the combination can raise blood pressure.

Several of these are manageable with practical counseling. Following a reduced-calorie diet, staying well hydrated, and avoiding high-fat foods and alcohol while on the medication all help minimize side effects and improve tolerability. The blood-pressure effect and the insomnia, however, are not purely comfort issues — they connect directly to the warnings below and to who should and should not take the drug.

Warnings and contraindications

Because Contrave contains bupropion, it inherits bupropion's most important safety considerations. First is seizure risk: bupropion lowers the seizure threshold, which makes a history of seizures a hard stop. Second is the antidepressant-class boxed warning for suicidality and neuropsychiatric changes — the warning that applies to bupropion in its antidepressant context regarding suicidal thoughts and behavior, particularly relevant when treating patients with psychiatric conditions. Providers must take both seriously and screen for them before prescribing.

The medication is contraindicated in several specific populations:

• Uncontrolled hypertension — the drug can raise blood pressure, so it is inappropriate where blood pressure is not already controlled.
• Seizure disorder — bupropion lowers the seizure threshold; a seizure history is a contraindication.
• Chronic opioid use — naltrexone is an opioid antagonist and will precipitate withdrawal or block needed opioid therapy.
• Eating disorders — a history of bulimia or anorexia nervosa is a contraindication, in part because of the elevated seizure risk in this population.

This contraindication list is not a formality. Screening for seizure history, current opioid use, uncontrolled hypertension, and disordered eating is the gating step that separates a good candidate from a dangerous prescription, and it should happen in every patient before the first dose.

Who it suits

The mechanism points directly at the ideal candidate. Because naltrexone targets the reward pathway, Contrave is most logically matched to patients whose eating is driven by food cravings, reward-seeking, or emotional eating rather than by large portion sizes alone — the patient who is not necessarily hungrier than anyone else but is pulled toward food by its reward value. For that pattern, a drug that quiets craving can succeed where appetite-volume strategies fall short.

The combination can also be an elegant fit for patients with overlapping indications. A patient who carries excess weight and is also depressed, or who is trying to quit smoking, may benefit from bupropion's primary FDA-approved effects at the same time. Matching the agent to the whole patient — their eating pattern and their comorbidities — is precisely the kind of judgment that distinguishes competent weight-loss prescribing, and it is covered in depth in Empire's medical weight loss training.

Monitoring

Deliberately, this overview does not publish specific starting doses, titration steps, or the day-by-day escalation schedule for Contrave. Those numbers belong to current FDA labeling and to individualized clinical judgment, and Empire's training covers the stepwise approach in detail. What can be said in general terms is that the relevant monitoring follows from the warnings: blood pressure and heart rate should be checked given the medication's pressor effect, and patients — especially those with psychiatric history — should be observed for mood changes and neuropsychiatric symptoms consistent with the boxed warning. As with every agent in this class, efficacy and tolerability should be reassessed on an ongoing basis, with the drug continued only while it is delivering benefit at an acceptable cost.

Training and how providers prescribe

Naltrexone-bupropion is a clear illustration of why combination weight-loss agents reward real education. The drug is only as good as the match between its mechanism and the patient, and that match depends on understanding two pharmacologies at once, recognizing the reward-eating phenotype it is built for, and screening a contraindication list where a missed seizure or opioid history can cause genuine harm. None of that is intuitive from a package insert alone.

Empire's curriculum is built around exactly this kind of practical judgment, situating Contrave within the full pharmacologic toolkit alongside agents such as phentermine-topiramate (Qsymia), the stimulant and lipotropic options, and the GLP-1 class. For the broader landscape of agents, see our overview of weight-loss medications and, from the peptide side of the field, semaglutide.